Targeted therapy and immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- Your liver cancer cannot be removed with surgery, or it is at an intermediate or advanced stage.
- Your liver function is adequate (Child-Pugh class A or score of 7) and you are generally able to care for yourself (ECOG score 0-2).
- You are willing to receive targeted therapy combined with immunotherapy, or a combination of two immunotherapies.
- Your blood counts and organ function are within acceptable limits (e.g., platelets, hemoglobin, liver enzymes).
- You have not had serious bleeding from varices (enlarged veins in the esophagus or stomach) in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery. One treatment delivers chemotherapy directly to the tumor, and the other uses tiny beads to block the tumor's blood supply. This approach may help shrink tumors and slow the cancer's growth.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.